Sequenom: Forbes ‘Stock of the Week’
January 22nd, 2009From Forbes:
Sequenom, Inc., the company promising a more accurate prenatal blood test for Down syndrome, is selected as the Forbes.com “Stock of the Week.”
One promising prenatal test that has helped to propel shares of Sequenom is one that uses noninvasive prenatal diagnostic technology to quantify maternal plasma DNA sequences for fetal Trisomy 21, or Down syndrome. Early testing in Hong Kong of pregnant women in the first and second trimesters of pregnancy was promising. Of the 28 subjects under observation, all 14 cases of Down syndrome were correctly identified.
… Closing at $25.54 on Wednesday, shares of Sequenom are up 202% in the past 12 months, and about 15% off of their 52-week high of $29.14 on Sept. 25, 2008. Shares got down to $12.71 on Nov. 20 but have since doubled.
Our RSS Feed